Table V.
Change in Renal Function
| Reference, Year | Baseline eGFR, mL/min/1.73 m2 | Baseline Creatinine, μmol/L | Follow‐Up Interval | Change in eGFR | Change in Creatinine | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | C | I | C | I | C | P Value | I | C | P Value | ||
| Randomized control trials | |||||||||||
| Ukena (2011) | 70±24 | 64.5±16 | NR | NR | 3 mo | NR | NR | NR | NR | ||
| Symplicity HTN‐2 (2010) | 77±19 | 86±20 | 91±25 | 78±18 | 6 mo | 0.2 | 0.9 | .76 | 0.2 | −1.1 | .67 |
| Case‐control studies | |||||||||||
| Mahfoud (2012) | 84.6±3.6a | 97.9±7.4a | NR | NR | 3 mo | −4.2 | −9.4 | NS | NR | ||
| 6 mo | −4.0 | −15.1 | NS | NR | |||||||
| Brandt (2012) | 83.5±27.8 | 80.5±29.3 | 86.2±26.4 | 86.2±44 | 1 mo | −3.5 | +0.4 | NS | +2.6 | +0.9 | NS |
| 6 mo | +1.2 | +9.5 | NS | −4.3 | −7 | NS | |||||
| Mahfoud (2011) | 75.1±3.3 | 81.0±7.6 | NR | NR | 3 mo | NR | NR | NR | NR | ||
| Krum (2009) | 79±21 | 95±15 | NR | NR | 6 mo | 4 | NR | NR | NR | NR | |
| Case series | |||||||||||
| Hering (2012) | 31.2±8.9 | 186.7±64.4 | 6 mo | −2.16 | .22 | 30.7 | .28 | ||||
| Prochnau (2012) | NR | >130 | 6 mo | NR | No change | ||||||
| Prochnau (2012) | NR | >130 | 3 mo | NR | No change | ||||||
| Vase (2012) | 78±13 | 79±20 | 1 mo | 1 | NS | 5 | NS | ||||
| Symplicity HTN‐1 (2011) | 83±20 | NR | 12 mo | −2.9 | NR | NR | |||||
| 24 mo | −16 | ||||||||||
| Simonetti (2011) | 91.6±15 | NR | 2 mo | 0 | NR | ||||||
| Voskuil (2011) | 74±14 | 78±17 | 1 mo | NR | 0 | .92 | |||||
| Witkowsky (2011) | 81.3 | NR | 6 mo | No change | No change | ||||||
Abbreviations: C, control group; eGFR, estimated glomerular filtration rate; I, intervention group; NR, not reported. aCystatin C GFR.